Skip to main content
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 95.24
Day High 97.98
Open:96.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
JPMorgan Chase & Co. is a financial services firm. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management and private equity. It offers various investment banking products and services, including advising on corporate strategy and structure, capital-raising in equity and debt markets, risk management, market-making in cash securities and derivative instruments, prime brokerage. It also offers consumer and business, and mortgage banking products and services that include checking and savings accounts, mortgages, home equity and business loans, and investments. JPMorgan Chase & Co. is headquartered in New York.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Atea Pharmaceuticals Announces Pricing of Initial Public Offering
- GlobeNewswire - Thu Oct 29, 7:00PM CDT
GlobeNewswire - CMTX
Thu Oct 29, 7:00PM CDT
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of $24.00 per share. All of the shares of common stock are being offered by Atea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Atea, are expected to be $300 million, excluding any exercise of the underwriters' option to purchase additional shares. Atea's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVIR" on October 30, 2020. The offering is expected to close on November 3, 2020, subject to satisfaction of customary closing conditions. In addition, Atea has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Atea's common stock at the initial public offering price less the underwriting discounts and commissions.
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds JPMorgan Chase & Co. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm - JPM
- BusinessWire - Thu Oct 29, 1:30PM CDT
BusinessWire - CMTX
Thu Oct 29, 1:30PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of JPMorgan Chase & Co. (NYSE: JPM) between February 23, 2016 and September 23, 2020, inclusive (the "Class Period"), of the important December 23, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for JPMorgan investors under the federal securities laws.
TechnipFMC to Present ESG Update at the J.P. Morgan Energy Technology Tour
- BusinessWire - Thu Oct 29, 12:15PM CDT
BusinessWire - CMTX
Thu Oct 29, 12:15PM CDT
Regulatory News:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 95.09 +2.19% increase
on 10/02/20
Period Open:95.35
Price movement based on the high, low and last over the given period.
104.45 -6.97% decrease
on 10/23/20
+1.82 (+1.91%) increase
since 09/29/20
3-Month 91.38 +6.34% increase
on 09/24/20
Period Open:99.68
Price movement based on the high, low and last over the given period.
106.43 -8.70% decrease
on 08/12/20
-2.51 (-2.52%) decrease
since 07/29/20
52-Week 76.91 +26.34% increase
on 03/19/20
Period Open:126.43
Price movement based on the high, low and last over the given period.
141.10 -31.13% decrease
on 01/02/20
-29.26 (-23.14%) decrease
since 10/29/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies